Restricted accessResearch articleFirst published online 2013-11
Frataxin Deficiency Leads to Defects in Expression of Antioxidants and Nrf2 Expression in Dorsal Root Ganglia of the Friedreich's Ataxia YG8R Mouse Model
Aims: Oxidative stress is thought to be involved in Friedreich's ataxia (FRDA), yet it has not been demonstrated in the target neurons that are first to degenerate. Using the YG8R mouse model of FRDA, microarray and neuritic growth experiments were carried out in the dorsal root ganglion (DRG), the primary site of neurodegeneration in this disease. Results: YG8R hemizygous mice exhibited defects in movement, and DRG neurites had growth defects. Microarray of DRG tissue identified decreased transcripts encoding the antioxidants, including peroxiredoxins, glutaredoxins, and glutathione S-transferase, and these were confirmed by immunoblots and quantitative real-time PCR. Because the decreased gene transcripts are the known targets of the antioxidant transcription factor nuclear factor-E2-related factor-2 (Nrf2), Nrf2 expression was measured; it was significantly decreased at the transcript and protein level in both the DRG and the cerebella of the YG8R hemizygous mouse; further, frataxin expression was significantly correlated with Nrf2 expression. Functionally, in YG8R hemizygous DRG, the total glutathione levels were reduced and explanted cells were more sensitive to the thioredoxin reductase (TxnRD) inhibitor auranofin, a thiol oxidant. In cell models of FRDA, including Schwann and the DRG, frataxin deficiency caused a decreased expression of the Nrf2 protein level in the nucleus, but not a defect in its translocation from the cytosol. Further, frataxin-deficient cells had decreased enzyme activity and expression of TxnRD, which is regulated by Nrf2, and were sensitive the TxnRD inhibitor auranofin. Innovation and Conclusion: These results support a mechanistic hypothesis in which frataxin deficiency decreases Nrf2 expression in vivo, causing the sensitivity to oxidative stress in target tissues the DRG and the cerebella, which contributes to the process of neurodegeneration. Antioxid. Redox Signal. 19, 1481–1493.
Al-MahdawiS, PintoRM, VarshneyD, LawrenceL, LowrieMB, HughesS, WebsterZ, BlakeJ, CooperJM, KingR, PookMA. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics, 88:580–590. 2006.
5.
AndersonPR, KirbyK, HillikerAJ, PhillipsJP. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet, 14:3397–3405. 2005.
6.
AndersonPR, KirbyK, OrrWC, HillikerAJ, PhillipsJP. Hydrogen peroxide scavenging rescues frataxin deficiency in a Drosophila model of Friedreich's ataxia. Proc Natl Acad Sci U S A, 105:611–616. 2008.
7.
AuchereF, SantosR, PlanamenteS, LesuisseE, CamadroJM. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia. Hum Mol Genet, 17:2790–2802. 2008.
8.
BannisterJV, BannisterWH, RotilioG. Aspects of the structure, function, and applications of superoxide dismutase. CRC Crit Rev Biochem, 22:111–180. 1987.
9.
BenomarA, YahyaouiM, MeggouhF, BouhoucheA, BoutchichM, BouslamN, ZaimA, SchmittM, BelaidiH, OuazzaniR, ChkiliT, KoenigM. Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. J Neurol Sci, 198:25–29. 2002.
10.
BradleyJL, BlakeJC, ChamberlainS, ThomasPK, CooperJM, SchapiraAH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet, 9:275–282. 2000.
11.
Bridwell-RabbJ, WinnAM, BarondeauDP. Structure-function analysis of friedreich's ataxia mutants reveals determinants of frataxin binding and activation of the Fe-S assembly complex. Biochemistry, 50:7265–7274. 2011.
12.
BulteauAL, DancisA, GareilM, MontagneJJ, CamadroJM, LesuisseE. Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med, 42:1561–1570. 2007.
13.
BulteauAL, PlanamenteS, JorneaL, DurA, LesuisseE, CamadroJM, AuchereF. Changes in mitochondrial glutathione levels and protein thiol oxidation in yfh1 yeast cells and the lymphoblasts of patients with Friedreich's ataxia. Biochim Biophys Acta, 1822:212–225. 2012.
CalkinsMJ, JohnsonDA, TownsendJA, VargasMR, DowellJA, WilliamsonTP, KraftAD, LeeJM, LiJ, JohnsonJA. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal, 11:497–508. 2009.
16.
CampuzanoV, MonterminiL, LutzY, CovaL, HindelangC, JiralerspongS, TrottierY, KishSJ, FaucheuxB, TrouillasP, AuthierFJ, DurrA, MandelJL, VescoviA, PandolfoM, KoenigM. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet, 6:1771–1780. 1997.
17.
CampuzanoV, MonterminiL, MoltoMD, PianeseL, CosseeM, CavalcantiF, MonrosE, RodiusF, DuclosF, MonticelliA, ZaraF, CanizaresJ, KoutnikovaH, BidichandaniSI, GelleraC, BriceA, TrouillasP, De MicheleG, FillaA, De FrutosR, PalauF, PatelPI, Di DonatoS, MandelJL, CocozzaS, KoenigM, PandolfoM. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271:1423–1427. 1996.
18.
Chantrel-GroussardK, GeromelV, PuccioH, KoenigM, MunnichA, RotigA, RustinP. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet, 10:2061–2067. 2001.
19.
ChaoPL, FanSF, ChouYH, LinAM. N-acetylcysteine attenuates arsenite-induced oxidative injury in dorsal root ganglion explants. Ann N Y Acad Sci, 1122:276–288. 2007.
20.
ChelikaniP, FitaI, LoewenPC. Diversity of structures and properties among catalases. Cell Mol Life Sci, 61:192–208. 2004.
21.
CosseeM, PuccioH, GansmullerA, KoutnikovaH, DierichA, LeMeurM, FischbeckK, DolleP, KoenigM. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet, 9:1219–1226. 2000.
22.
CoxAG, BrownKK, ArnerES, HamptonMB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol, 76:1097–1109. 2008.
DasKC, WhiteCW. Redox systems of the cell: possible links and implications. Proc Natl Acad Sci U S A, 99:9617–9618. 2002.
25.
DurrA, CosseeM, AgidY, CampuzanoV, MignardC, PenetC, MandelJL, BriceA, KoenigM. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med, 335:1169–1175. 1996.
26.
EmondM, LepageG, VanasseM, PandolfoM. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology, 55:1752–1753. 2000.
27.
FengZ, LiuZ, LiX, JiaH, SunL, TianC, JiaL, LiuJ. alpha-Tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. J Nutr Biochem, 21:1222–1231. 2010.
28.
FillaA, De MicheleG, CavalcantiF, PianeseL, MonticelliA, CampanellaG, CocozzaS. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet, 59:554–560. 1996.
29.
FinocchiaroG, BaioG, MicossiP, PozzaG, di DonatoS. Glucose metabolism alterations in Friedreich's ataxia. Neurology, 38:1292–1296. 1988.
30.
GromerS, ArscottLD, WilliamsCHJr., SchirmerRH, BeckerK. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem, 273:20096–20101. 1998.
31.
HardingAE, HewerRL. The heart disease of Friedreich's ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases. Q J Med, 52:489–502. 1983.
32.
HaugenAC, Di ProsperoNA, ParkerJS, FanninRD, ChouJ, MeyerJN, HalwegC, CollinsJB, DurrA, FischbeckK, Van HoutenB. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology. PLoS Genet, 6:e1000812. 2010.
33.
HirokawaN, NodaY. Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev, 88:1089–1118. 2008.
34.
IlievaH, PolymenidouM, ClevelandDW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol, 187:761–772. 2009.
35.
InnamoratoNG, RojoAI, Garcia-YagueAJ, YamamotoM, de CeballosML, CuadradoA. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol, 181:680–689. 2008.
36.
JauslinML, WirthT, MeierT, SchoumacherF. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet, 11:3055–3063. 2002.
37.
KalininaEV, ChernovNN, SaprinAN. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc), 73:1493–1510. 2008.
38.
KoeppenAH, MichaelSC, KnutsonMD, HaileDJ, QianJ, LeviS, SantambrogioP, GarrickMD, LamarcheJB. The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol, 114:163–173. 2007.
39.
KoeppenAH, MorralJA, DavisAN, QianJ, PetrocineSV, KnutsonMD, GibsonWM, CusackMJ, LiD. The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol, 118:763–776. 2009.
40.
KollbergG, TuliniusM, MelbergA, DarinN, AndersenO, HolmgrenD, OldforsA, HolmeE. Clinical manifestation and a new ISCU mutation in iron-sulphur cluster deficiency myopathy. Brain, 132:2170–2179. 2009.
41.
KongL, TanitoM, HuangZ, LiF, ZhouX, ZahariaA, YodoiJ, McGinnisJF, CaoW. Delay of photoreceptor degeneration in tubby mouse by sulforaphane. J Neurochem, 101:1041–1052. 2007.
42.
KwakMK, WakabayashiN, ItohK, MotohashiH, YamamotoM, KenslerTW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem, 278:8135–8145. 2003.
43.
LefevreS, BrossasC, AuchereF, BoggettoN, CamadroJM, SantosR. Apn1 AP-endonuclease is essential for the repair of oxidatively damaged DNA bases in yeast frataxin-deficient cells. Hum Mol Genet, 21:4060–4072. 2012.
44.
LiH, OuttenCE. Monothiol CGFS Glutaredoxins and BolA-like Proteins: [2Fe-2S] Binding Partners in Iron Homeostasis. Biochemistry, 51:4377–4389. 2012.
MaherP. Redox control of neural function: background, mechanisms, and significance. Antioxid Redox Signal, 8:1941–1970. 2006.
47.
McMahonM, LamontDJ, BeattieKA, HayesJD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A, 107:18838–18843. 2010.
48.
MeijeringE, JacobM, SarriaJC, SteinerP, HirlingH, UnserM. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A, 58:167–176. 2004.
49.
MochelF, KnightMA, TongWH, HernandezD, AyyadK, TaivassaloT, AndersenPM, SingletonA, RouaultTA, FischbeckKH, HallerRG. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet, 82:652–660. 2008.
50.
MonterminiL, RichterA, MorganK, JusticeCM, JulienD, CastellottiB, MercierJ, PoirierJ, CapozzoliF, BouchardJP, LemieuxB, MathieuJ, VanasseM, SeniMH, GrahamG, AndermannF, AndermannE, MelanconSB, KeatsBJ, Di DonatoS, PandolfoM. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol, 41:675–682. 1997.
51.
NguyenT, SherrattPJ, NioiP, YangCS, PickettCB. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem, 280:32485–32492. 2005.
52.
NjalssonR, NorgrenS. Physiological and pathological aspects of GSH metabolism. Acta Paediatr, 94:132–137. 2005.
53.
PastoreA, TozziG, GaetaLM, BertiniE, SerafiniV, Di CesareS, BonettoV, CasoniF, CarrozzoR, FedericiG, PiemonteF. Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia: a potential role in the pathogenesis of the disease. J Biol Chem, 278:42588–42595. 2003.
54.
PatelVP, ChuCT. Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol, 4:215–229. 2011.
PiemonteF, PastoreA, TozziG, TagliacozziD, SantorelliFM, CarrozzoR, CasaliC, DamianoM, FedericiG, BertiniE. Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest, 31:1007–1011. 2001.
57.
PompellaA, VisvikisA, PaolicchiA, De TataV, CasiniAF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol, 66:1499–1503. 2003.
58.
PondarreC, CampagnaDR, AntiochosB, SikorskiL, MulhernH, FlemingMD. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood, 109:3567–3569. 2007.
59.
PuccioH, SimonD, CosseeM, Criqui-FilipeP, TizianoF, MelkiJ, HindelangC, MatyasR, RustinP, KoenigM. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet, 27:181–186. 2001.
60.
RadiskyDC, BabcockMC, KaplanJ. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem, 274:4497–4499. 1999.
61.
RistowM, MulderH, PomplunD, SchulzTJ, Muller-SchmehlK, KrauseA, FexM, PuccioH, MullerJ, IskenF, SprangerJ, Muller-WielandD, MagnusonMA, MohligM, KoenigM, PfeifferAF. Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest, 112:527–534. 2003.
62.
RosenDR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 364:362. 1993.
63.
RotigA, de LonlayP, ChretienD, FouryF, KoenigM, SidiD, MunnichA, RustinP. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet, 17:215–217. 1997.
64.
RunkoAP, GriswoldAJ, MinKT. Overexpression of frataxin in the mitochondria increases resistance to oxidative stress and extends lifespan in Drosophila. FEBS Lett, 582:715–719. 2008.
SchmuckerS, MartelliA, ColinF, PageA, Wattenhofer-DonzeM, ReutenauerL, PuccioH. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One, 6:e16199. 2011.
ShanY, NapoliE, CortopassiG. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum Mol Genet, 16:929–941. 2007.
69.
ShidaraY, HollenbeckPJ. Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia. J Neurosci, 30:11369–11378. 2010.
70.
ShihAY, JohnsonDA, WongG, KraftAD, JiangL, ErbH, JohnsonJA, MurphyTH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci, 23:3394–3406. 2003.
StehlingO, ElsasserHP, BruckelB, MuhlenhoffU, LillR. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet, 13:3007–3015. 2004.
73.
TanG, NapoliE, TaroniF, CortopassiG. Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet, 12:1699–1711. 2003.
74.
ThierbachR, SchulzTJ, IskenF, VoigtA, MietznerB, DrewesG, von Kleist-RetzowJC, WiesnerRJ, MagnusonMA, PuccioH, PfeifferAF, SteinbergP, RistowM. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum Mol Genet, 14:3857–3864. 2005.
75.
TraberMG, AtkinsonJ. Vitamin E, antioxidant and nothing more. Free Radic Biol Med, 43:4–15. 2007.
76.
VarijaD, KumarKP, ReddyKP, ReddyVK. Prolonged constriction of sciatic nerve affecting oxidative stressors & antioxidant enzymes in rat. Indian J Med Res, 129:587–592. 2009.
77.
Vazquez-ManriqueRP, Gonzalez-CaboP, RosS, AzizH, BaylisHA, PalauF. Reduction of Caenorhabditis elegans frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutant. FASEB J, 20:172–174. 2006.
78.
WongA, YangJ, CavadiniP, GelleraC, LonnerdalB, TaroniF, CortopassiG. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet, 8:425–430. 1999.
79.
WongA, YangJ, DanielsonS, GelleraC, TaroniF, CortopassiG. Sensitivity of FRDA lymphoblasts to salts of transition metal ions. Antioxid Redox Signal, 2:461–465. 2000.
80.
WuKC, CuiJY, KlaassenCD. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci, 123:590–600. 2011.
81.
YeH, JeongSY, GhoshMC, KovtunovychG, SilvestriL, OrtilloD, UchidaN, TisdaleJ, CamaschellaC, RouaultTA. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest, 120:1749–1761. 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
